Latest Recurring Revenue News

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

Adherium Limited reports a remarkable 103% quarter-on-quarter growth in Remote Patient Monitoring subscription revenues for Q2 FY26, driven by strong device shipment momentum and strategic operational changes.

Vection Technologies reports a record quarter-to-date cash intake of approximately $14 million and a robust $50 million forward pipeline, underscoring strong momentum across defence, AI, healthcare, and retail sectors.

Metallium Ltd has secured a strategic partnership with ElementUSA to deploy its Flash Joule Heating technology for recovering gallium and scandium from red mud in Louisiana, backed by US$10.1 million in non-dilutive funding. This collaboration positions Metallium at the forefront of the US critical minerals supply chain expansion.

Axiom Properties, soon to be Axtec Limited, has forged a strategic partnership with Ray White Avi Khan Group to deploy cutting-edge embedded payments and automation solutions across 3,000 properties, aiming to transform real estate transactions and boost recurring revenue.

Intelligent Monitoring Group (IMG) is set to acquire Bluesky Holdco, owner of Tyco New Zealand and Red Wolf Security, in a deal expected to boost FY26 EBITDA by 28.3%. This move significantly strengthens IMG’s commercial security and fire services presence across Australasia.

Intelligent Monitoring Group has agreed to acquire Tyco NZ and Red Wolf for NZD 45 million, significantly boosting its New Zealand presence and FY26 earnings outlook.

Rent.com.au has achieved a significant milestone with RentBond® annuity revenue exceeding $100,000 in a single month, driven by over $1 million in new loans and strategic capital moves that improve profitability.

Stakk Limited reveals a striking 566% year-to-date growth in annual recurring revenue, driven by its pivot to a B2B embedded finance platform and strategic US market expansion. The company also secured a $15 million institutional placement, underpinning its ambitious growth plans.

Bell Financial Group reports a strong turnaround with a 17% rise in profit before tax for the 11 months to November 2025, driven by growth across key divisions and a robust second half.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

Memphasys is intensifying its direct sales efforts for the Felix™ sperm-selection device across key Middle East IVF clinics, positioning for rapid market activation upon CE Mark approval expected early 2026.